Table 2 Percentages of pathogens covered in bacteraemia presenting to the ED by different empiric antimicrobial regimens
Empiric antimicrobial treatment selection | % of covered pathogens(95%CI) | % of covered pathogens, new EUCAST recommendations (95%CI) | p-Value | Bacteria without sufficient coverage |
|---|---|---|---|---|
Aminopenicillin-beta-lactamase inhibitor combinations (ampicillin-sulbactam) | 60.5% (56.8%;64.4%) | 63.9% (60.4%;67.8%) | p < 0.001 | ESBL-Enterobacterales, Pseudomonas aeruginosa, Enterococcus faecium, MRSA |
Ureidopenicillin-beta-lactamase inhibitor combinations (piperacillin-tazobactam) | 83.2% (80.1%;85.9%) | 92.8% (90.6%;94.6%) | p < 0.001 | Enterococcus faecium MRSA |
2nd generation cephalosporins (cefuroxime) | 72.3% (69.7%;76.5%) | 75.4% (72.9%;79.5%) | p < 0.001 | ESBL- Enterobacterales, Pseudomonas aeruginosa, Enterococcus spp., MRSA |
3rd generation cephalosporins (ceftriaxone) | 82.0% (79%;84.9%) | 82.1% (79%;84.9%) | p = 1.000 | ESBL- Enterobacterales, Pseudomonas aeruginosa, Enterococcus spp., MRSA |
Carbapenems (imipenem or meropenem) | 97.0% (95.6%;98.2%) | 97.5% (96.2%;98.6%) | p = 0,250 | Enterococcus faecium MRSA |
COMBINATION REGIMENS | ||||
Piperacillin-tazobactam + vancomycin | 85.0% (81.9%;87.5%) | 94.6% (92.5%;96.1%) | p < 0.001 | |
carbapenems (meropenem/ imipenem) + vancomycin | 98.8% (97.8%;99.5%) | 99.3% (98.4%;99.7%) | p = 0,250 | |
Piperacillin-tazobactam + linezolid | 85.0% (82.1%;87.6%) | 94.6% (92.7%;96.2%) | p < 0.001 | |
Carbapenem (meropenem/ imipenem) + linezolid | 98.8% (98%;99.6%) | 99.3% (98.6%;99.8%) | p = 0,250 | |